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Conclusions:
Due to the overlapping clinical spectrum of both, HPMRS and MCAHS, in the 77 majority of affected individuals, the elevation of AP and the reduced surface levels of linked markers in both groups, a common classification as GPIBDs is recommended. The 79 effectiveness of computer-assisted gestalt analysis for the correct gene inference in a GPIBD 80 and probably beyond is remarkable and illustrates how the information contained in human 81 faces is pivotal in the delineation of genetic entities. 82
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Inherited deficiencies of the glycosylphosphatidylinositol (GPI) biosynthesis are a 86 heterogeneous group of recessive Mendelian disorders that all share a common feature: The 87 function of GPI-linked proteins is compromised due to a defect in the GPI-anchor synthesis or 88 modification. Most of the enzymes involved in this molecular pathway are known and the 89 biochemical steps are well described [1] . With respect to the effect of genetic mutations on 90 the anchor and the GPI-linked substrate, several subdivisions of the pathway have been in use: 91 1) Early GPI-anchor synthesis, 2) Late GPI-anchor synthesis, 3) GPI transamidase, and 4) 92
Remodeling of fatty acids of the GPI-anchor after attachment to proteins ( Figure S1 ). 93
The last two groups are defined by their molecular actions and comprise the genes GPAA1, 94 PIGK, PIGU, PIGS, and PIGT, for the GPI-transamidase and PGAP1, PGAP2, PGAP3, 95 MPPE1, and TMEM8 for the fatty acid remodeling. The differentiation between early and late 96 GPI-anchor synthesis considers the molecular consequence of the GPIBD and it was 97 suggested after an important finding from Murakami et al., regarding the release of alkaline 98 phosphatase (AP) -a GPI-anchored marker [2] : If the anchor synthesis is stuck at an earlier 99 step, the transamidase does not get active and the hydrophobic signal peptide of GPI-anchor 100 substrates is not cleaved. As soon as the first mannose residue on the GPI-anchor has been 101 added by PIGM, the transamidase tries to attach the substrate to the anchor. However, if 102 subsequent steps are missing, the GPI-anchored proteins (GPI-APs) might be less stable and 103 hyperphosphatasia was hypothesized to be a consequence thereof. 104
The activity of the AP was regarded as such a discriminatory feature that it resulted in the 105 phenotypic series HPMRS 1 to 6, comprising currently the six genes PGAP2, PGAP3, PIGV, 106 PIGO, . Whenever a pathogenic mutation was discovered in a new gene 107 of the GPI-pathway and the developmentally delayed individuals showed an elevated AP in 108 the serum, the gene was simply added to this phenotypic series. If hyperphosphatasia was 109 missing, the gene was linked to another phenotypic series, Multiple Congenital Anomalies-110 Hypotonia-Seizures (MCAHS) that currently consists of PIGA, PIGN, . 111 However, the convention of dividing newly discovered GPIBDs over these two phenotypic 112 subgroups is only reasonable if they really represent distinguishable entities. This practice is 113 now challenged by a growing number of exceptions. The expressivity of most features is 114 variable and even the AP seems to be a biomarker with some variability: Some individuals 115 with mutations in PIGA also show elevated AP levels [10, [13] [14] [15] , and some individuals with 116 mutations in PIGO, PGAP2 and PGAP3 show AP levels that are only borderline high [16] [17] [18] [19] . 117
Recently, deleterious mutations were identified in PIGC, PIGP and PIGG in individuals with 118 intellectual disability (ID), seizures and muscular hypotonia, but other features were missing 119 that were considered to be a prerequisite for MCAHS or HPMRS [20] [21] [22] . Despite of the large 120 phenotypic overlap with most GPIBDs, a flow cytometric analysis of granulocytes in 121 individuals with PIGG mutations did not show reduced surface levels for GPI-APs [20] [21] [22] . 122
However, in the meantime, Zhao et al. could show that an impairment of PIGG in fibroblasts 123 affects the marker expression, indicating that there might also be variability depending on the 124 tissue [23] . In concordance with these finding also a case report of an individual with ID and 125 seizures that has mutations in PIGQ, seems a suggestive GPIBD, in spite of negative FACS 126 results [24] . 127
The work of Markythanasis et al. can also be considered as a turning point in the naming 128 convention of phenotypes that are caused by deficiencies of the molecular pathway as OMIM 129 started now referring to them as a GPIBD (see OMIM entry #610293 for a discussion). In this 130 work we go one step further in this direction and ask the question whether also the phenotypic 131 series MCAHS and HPMRS should be abandoned in favor of a more gene-centered 132 description of the phenotype, which would also be in accordance with what Jaeken already 133 suggested for other congenital disorders of glycosylation [25] . Referring to GPIBD 134 phenotypes in a gene-specific manner makes particular sense if the gene can be predicted 135 from the phenotypic level with some accuracy. For this purpose, we analyzed systematically 136 the discriminatory power for GPIBDs for previously reported individuals as well as 23 novel 137 cases that were identified in routine diagnostics. This also adds in total novel FACS results of 138 16 patients on blood or fibroblasts, as well as 19 novel mutations ( Figure S2 ). 139
Apart from founder effects that explain the reoccurrence of certain mutations with higher 140 frequency, pathogenic mutations have now been reported in many exons ( Figure S2 ). 141
However, not much is known about genotype-phenotype correlations in these genes, which 142 makes bioinformatics interpretation of novel variants challenging. The phenotypic analysis, 143 for which we received ethics approval from the Charité University and obtained informed 144 consent from the responsible persons on behalf of all study participants, is based on three 145 different data sources, that is 1) a comprehensive clinical description of the phenotypic 146 features in , 2) flow-cytometric profiles of multiple GPI-linked 147 markers, and 3) computer-assisted pattern recognition on frontal photos of individuals with a 148 molecularly confirmed diagnosis. 149
The rationale behind flow cytometry and image analyses is that GPIBDs might differ in their 150 effect on GPI-APs and their trafficking pathways, resulting in distinguishable phenotypes. 151
Interestingly, we found that the facial gestalt was well suited for a delineation of the 152 molecular entity. The high information content of the facies has become accessible just 153 recently by advanced phenotypic tools that might also be used for the analysis of other 154 pathway disorders. Before we present the results of flow cytometry and of automated image 155 analysis we will review the most important phenotypic features of GPIBDs in the old schema 156 of phenotypic series HPMRS and MCAHS. 157 non-syndromic form of ID at one end of the clinical spectrum but also as a multiple 163 congenital malformation syndrome at the other end (Table S1 ). The distinct pattern of facial 164 anomalies of Mabry syndrome consist of wide set eyes, often with a large appearance and 165 upslanting palpebral fissures, a short nose with a broad nasal bridge and tip, and a tented 166 upper lip. The results of a computer-assisted comparison of the gene-specific facial gestalt 167 will be given in a later section. 168
Psychomotor delay, ID and variable AP elevation are the only consistent features of all 169 individuals with pathogenic mutations in PIGV [9, [27] [28] [29] [30] [31] [32] [33] , PIGO [7, 16, 17, 30, [34] [35] [36] 170 PGAP2 [4, 8, 18, 37] , PGAP3 [5, 19, [38] [39] [40] , PIGW [3, 41] , and PIGY [6]. Speech 171 development, especially expressive language, is more severely affected than motor skills in 172 the majority of the affected individuals (Table S1 ). Absent speech development was observed 173 in more than half of the affected individuals. Speech difficulties may be complicated by 174
hearing loss, which is present in a minority of affected individuals. In the different genetic 175 groups, seizures of various types and onset are present in about 65% of affected individuals. 176
Most affected individuals show a good response to anticonvulsive drugs, however, a few 177 affected individuals are classified as drug resistant and represent the clinically severe cases 178 (individual 14-0585). Muscular hypotonia is common in all types of HPMRS (about 65%). 179
Behavioral problems, in particular sleep disturbances and autistic features, tend to be frequent 180 (87%) in affected individuals with PGAP3 mutations and are described in a few affected 181 individuals with PIGY mutations but are not documented in affected individuals with 182 mutations in the other four genes. Furthermore, ataxia and unsteady gait have been 183 documented in almost half of the affected individuals carrying PGAP3 mutations and about a 184 third of this group did not achieve free walking at all. 185
Elevated values of AP were the key finding in affected individuals. However, a few cases are 186 documented with only minimal elevation of this parameter. The degree of persistent 187 hyperphosphatasia in the reported affected individuals varies over a wide range between about 188 1.1 and 17 times the age-adjusted upper limit of the normal range. The mean elevation of AP 189 is about 5 to 6 times the upper limit. Measurements at different ages of one individual show 190 marked variability of this value, for example from two times to seven times the upper limit. 191 There is no association between the AP activity and the degree of neurological involvement. in the group of affected individuals with PGAP3 mutations with a prevalence of almost 60%, 213 whereas other malformations are rarely observed. Exceptional is a group of 10 Egyptian 214 individuals with the same founder mutation and a high incidence of structural brain anomalies 215 (thin corpus callosum (8/10), vermis hypoplasia (4/10), ventriculomegaly (3/10) and Walker malformation (1/10) [28, 38] . Up to date these are the few individuals with a 217 presumable complete loss of function for this gene (NM_033419.3:c.402dupC, 218 p.Met135Hisfs*28; c.817_820 delGACT, p.Asp273Serfs*37)). 219
Malformations had not been observed in the single reported affected individual with PIGW 220 mutations [3] . Apart from dilation of renal collecting systems, affected individuals with PIGY 221 mutations presented with a new spectrum of organ involvement such as cataracts, rhizomelic 222 shortness of limbs, contractures and hip dysplasia [6] . 223
All affected individuals with PIGV and PIGO mutations had a variable degree of distal hand 224 anomalies, namely brachytelephalangy. They showed hypoplastic finger nails as well as 225 hypoplastic distal phalanges in the hand X-rays. Often, they displayed broad and short distal 226 phalanges of the thumbs and halluces including short and broad corresponding nails of the 227 affected digits. Brachytelephalangy is not present in any of the affected individuals with 228 PGAP3, PGAP2 and PIGW mutations, respectively, although one third showed broad nails 229 without radiological abnormalities in the available X-rays. One of four affected individuals 230 with PIGY mutations showed brachytelephalangy. 231 A multidisciplinary approach is required to manage the GPIBDs described in this section, as 232 the clinical variability is broad. It is recommended that all affected individuals have at least 233 one baseline renal ultrasound investigation as well as an echocardiography to rule out any 234 obvious malformations. In case of chronic obstipation, Hirschsprung disease, as well as anal 235 anomalies should be excluded. Hearing evaluation is recommended in all affected individuals. 236
Individuals with behavioral problems may benefit from a review by a clinical psychologist. 237
Regular developmental assessments and EEG investigations are required to ensure that 238 affected individuals get optimal support. The tendency towards epilepsies has been reported to 239 decrease in some affected individuals with growing age and if the affected individual and 240 physician agree to a trial discontinuation of therapy, medications could be tapered. 241
242
Clinical overview of MCAHS: MCAHS comprises a group of genetically different disorders 243 characterized by early onset forms of different types of epilepsies with poor prognosis, 244 missing or minimal psychomotor development and often, early death (Table S2 ). The 245 phenotypic series include individuals with PIGA (MIM 300868) [10, [13] [14] [15] [42] [43] [44] [45] [46] , PIGN 246 (MIM 614080) [12, 18, [47] [48] [49] [50] [51] [52] [53] , and PIGT (MIM 615398) [11, 39, [54] [55] [56] [57] [10, [13] [14] [15] [42] [43] [44] [45] [46] . Macrocephaly or macrosomia occur in some of these 256 individuals, whereas microcephaly occurs in others. No distinct facial phenotype is 257 recognizable in comparison within and between the genetically different groups of MCAHS. 258
Interestingly, 5 out of 23 individuals with PIGA mutations had elevated AP measurements, 259
whereas only one individual with PIGN mutations was reported with borderline high AP 260
activity [52] . In contrast, some of the individuals with PIGT mutations showed decreased AP 261 [11, 39, 54, 57] . 262 HPMRS and MCAHS display an overlapping clinical spectrum but with a considerably worse 263 prognosis in MCAHS due to early onset and often intractable seizures as well as early death 264 in the majority of affected individuals. However, facial dysmorphisms do not appear to be 265 characteristic in the different types of MCAHS in contrast to HPMRS. Importantly, elevation 266 of AP and reduced surface levels of GPI linked substrates are not restricted to HPMRS. 267
Flow cytometry 268
Flow cytometry analysis of blood: 269
Flow cytometry was performed on granulocytes extracted from peripheral blood draws that 270 were sampled in BCT CytoChex tubes (Streck, USA, NE), shipped and analyzed in less than 271 72 hours. 50µl whole blood were mixed with 20µl of an antibody panel: The staining was incubated for 30min at room temperature followed by two washing steps 306 with 200µl FACS buffer. For flow cytometry analysis on a MACSQuant VYB the cells were 307 resuspended in 100µl FACS buffer. 308
Reduction of GPI-AP expression was calculated as a ration between the median fluorescence 309 intensity (MFI) of the patient against the mean of MFIs from healthy parents and a healthy 310 unrelated control. It is noteworthy that heterozygous carriers of pathogenic mutations 311 (parents) and unrelated healthy controls had only subtle differences in GPI-AP expression. 312 313
Computer-assisted phenotype comparison 314
Facial images of all individuals with a molecularly confirmed GPIBD were assessed with the 315 Face2Gene Research Application (FDNA Inv., Boston MA, USA). This software tool set 316 allows the phenotypic comparison of user-defined cohorts with ten or more individuals. The 317 classification model of Face2Gene Research uses a neural network architecture that consists 318 of ten convolutional layers, each but the last followed by batch normalization [Gurovich, et 319 al.] . The original collections are split into train/test sets for cross-validation and mean 320 accuracies for the classification process are computed. The result of a single experiment is a 321 confusion matrix that describes the performance of the classification process. As cohort size is 322 a known confounder, we randomly sampled all cohorts down to the same size (n=10) and 323 computed the mean true positive and error rates as well as the standard deviation from ten 324 iterations. The scripts for the simulations are available on request and can be used to 325 reproduce the results. 326
327
Results 328
Flow cytometric assessment of GPIBDs 329
We acquired fibroblast cultures of affected individuals to perform the measurements under the 330 same experimental conditions repeatedly. The marker FLAER that binds to the GPI-anchor 331 directly, as well as the GPI-APs CD55, CD59, and CD73 that show high expression levels on 332 fibroblasts were assessed (Figure 1 ). We hypothesized that measuring cell surface levels of 333 GPI-linked substrates directly by flow cytometry might be more suitable to quantify the 334 severity of a GPIBD or to predict the affected gene. No significant difference between 335 patients with MCAHS was observed compared to patients with HPMRS ( Figure 1a) . 336 Furthermore, the cell surface levels of CD55 and CD59 were in average lower in cells that 337 were derived from individuals with mutations in PGAP3 compared to individuals with 338 mutations in PIGV (Table S3 ), although this did not correspond to a higher prevalence to 339 seizures or a more severe developmental delay. CD55 and CD59 are of particular interest as 340 they protect cells from an attack of the activated complement system and the membrane attack 341 complex that has also been shown to be involved in the pathogenesis of seizures [58] . 342
The samples with pathogenic mutations in PIGV are noteworthy as they are derived from 343 individuals that differ considerably in the severity of their phenotype: 14-0585 was born with 344 multiple malformations and his seizures are resistant to treatment, whereas the other three 345 individuals A2, A3, and P1 are considered as moderately affected. The flow cytometric 346 profiles, however, do not show marked differences. Furthermore, the cell surface levels of 347 CD55 and CD59 were in average lower in cells that were derived from individuals with 348 mutations in PGAP3. (Table S4 ). Although individuals of the 355 MCAHS spectrum are usually more severely affected than individuals of the HPMRS 356 spectrum, we did not observe any significant differences for the tested markers (Figure 1 B) . 357
Thus, no significant correlation between FACS profiles of the two phenotypic series was 358 found. 359 360
Comparison of the facial gestalt of GPIBDs 361
The craniofacial characteristics of many Mendelian disorders are highly informative for 362 clinical geneticists and have also been used to delineate gene-specific phenotypes of several 363
GPIBDs [3-5, 10, 19, 27-29, 31, 38, 39, 43, 44, 59-61] . However, our medical terminology is 364 often not capable of describing subtle differences in the facial gestalt. Therefore, computer-365 assisted analysis of the gestalt has recently received much attention in syndromology and 366 several groups have shown that the clinical face phenotype space (CFPS) can also be 367 exploited by machine learning approaches [62] . If a recognizable gestalt exists, a classifier for 368 facial patterns can be trained to infer likely differential diagnoses. Conversely, if photos of 369 affected individuals with disease-causing mutations in different genes of a pathway form 370 separate clusters, it indicates that the gestalt is distinguishable to a certain extent. FDNA's 371 recently launched RESEARCH application is a deep learning tool for exactly this purpose 372 (https://app.face2gene.com/research): A classification model is generated on two or more 373 collections of frontal images and the performance is reported in means of a confusion matrix. 374
If true positive rates for the single gene-phenotypes are achieved that are significantly better 375 than for a random assignment of photos to cohorts, there is some phenotypic substructure and 376 the null-hypothesis of perfect heterogeneity may be rejected. 377
We used the RESEARCH app of the Face2Gene suite to evaluate a classifier for the five most 378 prevalent GPIBDs, that is PIGA (n=20), PIGN (n=11), PIGT (n=12), PIGV (n=25), and 379 PGAP3 (n=23) at the current moment. Our original sample set thus consists of frontal facial 380 photos of 91 individuals with a molecularly confirmed diagnosis of HPMRS or MCAHS, 381 including cases that have been previously published [5, 9-11, 13-15, 19, 27-29, 31-33, 38, 43, 382 47, 49, 50, 52-56, 60, 63] . The mean accuracy that is achieved on this original sample set is 383 52.2 %, which is significantly better than randomly expected. In order compare the 384 performances for the single gene classes we had to exclude confounding effects from 385 unbalanced cohort sizes and sampled the cohorts down to the same size of n=10. Although 386 this decreases the overall performance, the mean accuracy of 45.8% is still significantly better 387 than the 20% that would be achieved by chance in a 5-class-problem for evenly sized cohorts 388 ( Figure 2 ). Furthermore, for every single gene-phenotype, the true positive rate (TPR) was 389 better than randomly expected with PIGV achieving the highest value (59%). 390
Interestingly, we observed the highest false negative rate in the confusion matrix for PGAP3 391 (HPMRS4): In average these cases are erroneously classified as PIGV (HPMRS1) 32% of the 392 cases. This finding is in good agreement with the phenotypic delineation from 393 syndromologists that grouped these to genes in the same subclass. A cluster analysis of the 394 confusion matrix actually reproduces the two phenotypic series as shown by the dendrogram 395 in Figure 2 . 396 While the confusion matrix on the entire sample set can be used to decide whether there are 397 gene-specific substructures in the GPI-pathway, pairwise comparisons are better suited to 398 workup phenotypic differences between genes even inside a phenotypic series. We therefore 399 evaluated the area under the receiver operating characteristics curve (AUC) and found the 400 correct gene-prediction more often than randomly expected, including PIGV versus PGAP3 401 ( Figure S3 ). The differences in pair-wise comparison between PIGV and PGAP3 could be 402 confounded by the large number of Egyptian cases in the PGAP3 cohort [38] , the effect of 403 which we could not further analyze due to the limited set of patients photos. 404
405
Discussion 406 The identification of multiple affected individuals with GPIBDs has enabled the analysis of 407 genotype-phenotype relationships for the molecular pathway of GPI anchor synthesis. Besides 408 a developmental delay and seizures, which are common findings in most affected individuals 409 with a GPIBD, the clinical variability and the variation in expressivity is wide. So far, 410 recognizable gene-specific phenotypes seem to be accepted for PIGL and are discussed for 411 PIGM [64, 65] . For other GPIBDs the phenotypic series HPMRS and MCAHS have been 412 used to subgroup the pathway and the activity of the AP in the serum was the main 413 classification criterion. However, these disease entities are increasingly cumbersome as some 414
cases are now known that do not go along with this oversimplified rule. 415
We therefore compared GPIBDs based on deep phenotyping data and flow cytometric profiles 416 of GPI-APs. Among the 16 genes of the GPI pathway with reports of affected individuals, 417 mutations in PIGA, PIGN, PIGT, PIGV, and PGAP3 were most numerous and these GPIBDs 418 were also suitable for an automated image analysis. 419 A systematic evaluation of the phenotypic features showed that certain malformations occur 420 with a higher frequency in specific GPIBDs. To date, megacolon has only been found to be 421 associated with PIGV, PIGO, and PGAP2 mutations. Diaphragmatic defects have only been 422 documented in affected individuals with PIGN mutations. Only in individuals with PGAP3 423 mutations, behavioral problems, especially sleep disturbances and autistic features, are present 424 in about 90%. In addition, ataxia and unsteady gait are also frequently documented in this 425 group but not in the others. An accurate classification that is merely based on clinical 426 symptoms is, however, not possible due to their high variability. Also, flow cytometric 427 analysis of GPI-marker expressions were not indicative for the gene defect and did not 428 correlate with the severity of the phenotype. Of note is, however, that an assessment of the 429 GPI-AP expression levels seems more sensitive in the fibroblasts than in blood cells [23] . 430
This might also be related to the trafficking pathways of GPI-APs through ER and Golgi that 431 differ for cell types and substrates [66, 67] . 432
The overlapping clinical spectrum of both, HPMRS and MCAHS, the findings of elevated AP 433 and the reduced surface levels of GPI linked proteins in some of the MCAHS cases favor a 434 common classification as GPIBDs. 435 In light of the high variability and expressivity of the clinical findings and the weak genotype-436 phenotype correlation, the most surprising finding of our study was the high discriminatory 437
power that facial recognition technology achieved. In spite of the similarity of the 438 pathophysiology, differences in the gestalt are still perceptible. This illustrates the remarkable 439 information content of human faces and advocates for the power of computer-assisted 440 syndromology in the definition of disease entities. 441
Automated image analysis of syndromic disorders is a comparably new field of research and 442 the approach that we used requires photos of at least ten individuals per cohort. However, it is 443 currently not known if there is a minimum number of cases that is required to assess whether 444 a gene-phenotype is recognizable. Furthermore, for every rare disorder with a characteristic 445 gestalt there is possibly a maximum value for the recognizability. So far, the approximation of 446 this upper limit has not systematically been studied depending on the number of individuals 447 that were used in the training process and should definitely be a focus for future research. 
